Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

Virology. 2002 Mar 15;294(2):270-81. doi: 10.1006/viro.2001.1345.


Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Animals
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • Cell Line
  • Chlorocebus aethiops
  • Disease Models, Animal
  • Gene Products, env / genetics
  • Gene Products, env / immunology*
  • Gene Products, gag / genetics
  • Gene Products, gag / immunology*
  • Gene Products, pol / genetics
  • Gene Products, pol / immunology*
  • HIV Antibodies / immunology
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Immunization, Secondary
  • Macaca mulatta
  • Oligopeptides / immunology
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Simian Immunodeficiency Virus / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology*
  • Viral Load
  • env Gene Products, Human Immunodeficiency Virus


  • AIDS Vaccines
  • Gene Products, env
  • Gene Products, gag
  • Gene Products, pol
  • HIV Antibodies
  • Oligopeptides
  • Recombinant Fusion Proteins
  • Vaccines, DNA
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1